Not Yet RecruitingPhase 4

Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients

United States100 participantsStarted 2031-01-01

Plain-language summary

Our hypothesis is that S. aureus skin decolonization in atopic dermatitis reduces disease severity and favorably alters the function and gene expression of epidermal and immune skin cells that contribute to disease severity.

Who can participate

Age range6 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male or female participants ≥6 yrs of age
✓. Meet atopic dermatitis Standard Diagnostic Criteria
✓. SCORAD \> 40.

Exclusion criteria

✕. . Enrollment in another clinical trial
✕. Hypersensitivity to an agent used for the skin decolonization protocol
✕. Use within 4 weeks of systemic treatment with immunosuppressive/immunomodulating drugs (corticosteroids, cyclosporine, mycophenolate, azathioprine, methotrexate)
✕. Phototherapy for AD within 4 weeks
✕. Treatment with biologics (dupilumab, omalizumab, benralizumab, etc) within sixteen weeks
✕. Use of topical steroids, topical calcineurin inhibitors within 7 days
✕. Bleach baths within 7 days of the first Visit
✕. Use of oral or topical antibiotics within 21 days of the beginning of the study

What they're measuring

Severity Scoring of Atopic Dermatitis Index

Timeframe: 3 weeks

Trial details

NCT IDNCT06397781

SponsorBoston Children's Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2035-12

Contact for this trial

Principal Investigator

617-355-6000 asthma@childrens.harvard.edu

View on ClinicalTrials.gov More Atopic Dermatitis trials